Markets:

Overview

News

Currencies

International

Treasuries

Amneal Pharmaceuticals, Inc. - Class A Common Stock (NY:AMRX)

N/A UNCHANGED

Last Price Updated: 7:00 PM EST, Dec 26, 2023 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Amneal Pharmaceuticals, Inc. - Class A Common Stock

< Previous 1 2 3 4 5 6 7 Next >

The Daily Biotech Pulse: Cerus Climbs On Earnings, Horizon CFO To Retire, Teva Prices Upsized Sustainability-Linked Senior Note Offering ↗

November 03, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Horizon Announces Retirement Of CFO, Beat-and-raise Q3 Horizon Therapeutics...

Via Benzinga

Topics Retirement

Amneal Reports Third Quarter 2021 Financial Results

November 03, 2021

From Amneal Pharmaceuticals, Inc.

Via Business Wire

Amneal Releases Inaugural Corporate Responsibility Report Highlighting Our Impact as a Socially Responsible Company

November 02, 2021

From Amneal Pharmaceuticals, Inc.

Via Business Wire

The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight ↗

August 08, 2021

Biopharma stocks ended higher for the week ending Aug. 6, as the sector latched on to the optimism that was evident in the broader markets. Earnings continued to flow in,...

Via Benzinga

The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline ↗

October 31, 2021

Biotech stocks rose a third week running in the week ending Oct. 29 amid positive reaction to earnings. Big pharma earnings were mostly better than expected. Merck & Co, Inc...

Via Benzinga

Amneal Launches Generic Dexamethasone Following ANDA Approval by FDA

October 27, 2021

From Amneal Pharmaceuticals, Inc.

Via Business Wire

Mark Cuban-Owned Company To Launch Pharmacy Benefit Management Services ↗

October 25, 2021

Billionaire investor Mark Cuban is funding a new company focused on selling generic pharmaceuticals at a transparent fixed-rate markup. What Happened: The Mark Cuban Cost Plus...

Via Benzinga

Amneal to Report Third Quarter 2021 Results on November 3, 2021

October 06, 2021

From Amneal Pharmaceuticals, Inc.

Via Business Wire

Amneal to Virtually Participate at Morgan Stanley 19th Annual Global Healthcare Conference

September 07, 2021

From Amneal Pharmaceuticals, Inc.

Via Business Wire

The Daily Biotech Pulse: Early Approval For Ascendis' Pediatric Growth Hormone Deficiency Treatment, Redhill Biopharma Spikes On Positive COVID-19 Drug Data, RenovoRx IPO ↗

August 26, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 25) Abbvie Inc. (NYSE: ABBV)...

Via Benzinga

22 Stocks Moving in Thursday's Pre-Market Session ↗

August 26, 2021

Gainers Good Works Acquisition Corp. (NASDAQ: GWAC) rose 29.8% to $13.01 in pre-market trading. Good Works Acquisition and Cipher Mining reported shareholder approval of business...

Via Benzinga

Amneal's Parkinson's Candidate Shows Efficacy In Pivotal Trial ↗

August 26, 2021

Amneal Pharmaceuticals Inc (NYSE: AMRX) announced topline data from the Phase 3 RISE-PD trial evaluating IPX-203 in patients with Parkinson's disease who have...

Via Benzinga

12 Health Care Stocks Moving In Wednesday's After-Market Session ↗

August 25, 2021

Gainers Ascendis Pharma (NASDAQ:ASND) st...

Via Benzinga

Amneal Announces Positive Topline Results from Pivotal Phase 3 RISE-PD Clinical Trial of IPX-203 in Patients with Parkinson’s Disease Who Experience Motor Fluctuations

August 25, 2021

From Amneal Pharmaceuticals, Inc.

Via Business Wire

The Daily Biotech Pulse: Lilly Strikes $1.6B R&D Collaboration, FSD Pulls Plug On COVID-19 Program, Cassava Sinks On Questions About Alzheimer's Drug ↗

August 25, 2021

ere's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 24) Agenus Inc. (NASDAQ: AGEN)...

Via Benzinga

Amneal Announces Virtual Event to Discuss Initial Data from Pivotal Phase 3 Study of IPX-203 in Patients with Parkinson’s Disease Who Experience Motor Fluctuations

August 23, 2021

From Amneal Pharmaceuticals, Inc.

Via Business Wire

Amneal Pharmaceuticals, inc (AMRX) Q2 2021 Earnings Call Transcript ↗

August 09, 2021

AMRX earnings call for the period ending June 30, 2021.

Via The Motley Fool

Topics Earnings

Amneal Q2 Earnings Tops Estimates; Backs FY21 Guidance ↗

August 09, 2021

Amneal Pharmaceuticals Inc (NYSE: AMRX) reports Q2 revenue of $535 million, an increase of 15% Y/Y, beating the consensus of $523.25 million. Sales growth was driven by...

Via Benzinga

Amneal Pharmaceuticals: Q2 Earnings Insights ↗

August 09, 2021

Shares of Amneal Pharmaceuticals (NYSE:AMRX) moved higher by 0.6% in pre-market trading after the company reported Q2 results. Quarterly Results Earnings per share...

Via Benzinga

Amneal Reports Second Quarter 2021 Financial Results

August 09, 2021

From Amneal Pharmaceuticals, Inc.

Via Business Wire

The Daily Biotech Pulse: Ardelyx Sinks On Regulatory Setback, AnPac Issues Positive Preannouncement, European Nod For Myovant, HCW Biologics Debuts On Wall Street ↗

July 20, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 19) Cytokinetics, Incorporated...

Via Benzinga

Amneal Receives Approval for Generic TobraDex®

July 19, 2021

From Amneal Pharmaceuticals, Inc.

Via Business Wire

Amneal to Report Second Quarter 2021 Results on August 9, 2021

July 15, 2021

From Amneal Pharmaceuticals, Inc.

Via Business Wire

Amneal's Avastin-Referred Biosimilar Under FDA Review For Colorectal Cancer ↗

June 17, 2021

The FDA has accepted for review Amneal Pharmaceuticals Inc's (NYSE: AMRX) marketing application seeking approval for Bevacizumab, under Section 351(k) pathway...

Via Benzinga

Amneal Announces U.S. FDA Filing Acceptance of Biologics License Application (BLA) for Bevacizumab

June 17, 2021

From Amneal Pharmaceuticals, Inc.

Via Business Wire

Amneal Announces Dihydroergotamine (DHE) Autoinjector NDA for Migraines and Cluster Headaches

June 07, 2021

From Amneal Pharmaceuticals, Inc.

Via Business Wire

Amneal to Virtually Participate at Upcoming Investor Conferences

May 14, 2021

From Amneal Pharmaceuticals, Inc.

Via Business Wire

Amneal Pharmaceuticals, Inc. (AMRX) Q1 2021 Earnings Call Transcript ↗

May 07, 2021

AMRX earnings call for the period ending March 31, 2021.

Via The Motley Fool

Topics Earnings

12 Health Care Stocks Moving In Friday's After-Market Session ↗

May 07, 2021

Gainers Protagenic Therapeutics (NASDAQ:PTIX

Via Benzinga

The Daily Biotech Pulse: Split Verdict For Chemocentryx, NKarta-CRISPR In Cell Therapy Collaboration, Orphazyme's Clinical Trial Setback, 2 IPOs ↗

May 07, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 6) GT Biopharma, Inc. (NASDAQ:...

Via Benzinga

< Previous 1 2 3 4 5 6 7 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Amneal Pharmaceuticals, Inc. - Class A Common Stock (NY:AMRX)

All News about Amneal Pharmaceuticals, Inc. - Class A Common Stock

Starting at /week.